CO2020004669A2 - Derivados de bencimidazol y sus usos - Google Patents
Derivados de bencimidazol y sus usosInfo
- Publication number
- CO2020004669A2 CO2020004669A2 CONC2020/0004669A CO2020004669A CO2020004669A2 CO 2020004669 A2 CO2020004669 A2 CO 2020004669A2 CO 2020004669 A CO2020004669 A CO 2020004669A CO 2020004669 A2 CO2020004669 A2 CO 2020004669A2
- Authority
- CO
- Colombia
- Prior art keywords
- benzimidazole derivatives
- compound
- present
- trpc6
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención hace referencia a inhibidores de la actividad de proteínas de canal de potencial receptor transitorio 6 (TRPC6). La presente invención provee un compuesto de fórmula (I) o una sal farmacéuticamente aceptable de este, composiciones farmacéuticas que comprenden un compuesto de la invención, un método para fabricar compuestos de la invención y usos terapéuticos de estos. (I)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762574465P | 2017-10-19 | 2017-10-19 | |
US201862671090P | 2018-05-14 | 2018-05-14 | |
PCT/US2018/056484 WO2019079578A1 (en) | 2017-10-19 | 2018-10-18 | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020004669A2 true CO2020004669A2 (es) | 2020-05-05 |
Family
ID=66173507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0004669A CO2020004669A2 (es) | 2017-10-19 | 2020-04-16 | Derivados de bencimidazol y sus usos |
Country Status (19)
Country | Link |
---|---|
US (1) | US11332459B2 (es) |
EP (1) | EP3697410A4 (es) |
JP (1) | JP7450534B2 (es) |
KR (1) | KR20200074965A (es) |
CN (1) | CN111417394B (es) |
AU (1) | AU2018351059B2 (es) |
BR (1) | BR112020007589A8 (es) |
CA (1) | CA3079081A1 (es) |
CL (1) | CL2020001020A1 (es) |
CO (1) | CO2020004669A2 (es) |
IL (1) | IL273839B (es) |
MA (1) | MA50413A (es) |
MX (1) | MX2020003993A (es) |
PH (1) | PH12020550265A1 (es) |
SA (1) | SA520411787B1 (es) |
SG (1) | SG11202003502VA (es) |
TW (1) | TWI816704B (es) |
UY (1) | UY37941A (es) |
WO (1) | WO2019079578A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20200544A (es) | 2018-05-14 | 2021-02-11 | Gilead Sciences Inc | Inhibidores de mcl-1 |
KR20210136106A (ko) * | 2019-04-11 | 2021-11-16 | 데이진 화-마 가부시키가이샤 | 벤즈이미다졸 유도체 및 이들의 용도 |
TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
CN114787139A (zh) | 2019-11-26 | 2022-07-22 | 吉利德科学公司 | 用于制备mcl1抑制剂的方法和中间体 |
AR121846A1 (es) | 2020-04-16 | 2022-07-13 | Teijin Pharma Ltd | Derivado de arilo o heteroarilo |
CN117580577A (zh) * | 2021-06-29 | 2024-02-20 | 国立大学法人大阪大学 | 肾损伤的预防和/或治疗用医药组合物以及自噬活化剂 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2618435B1 (fr) | 1987-07-23 | 1989-10-27 | Synthelabo | Derives de benzimidazole, leur preparation et leur application en therapeutique |
US5670501A (en) | 1994-09-01 | 1997-09-23 | Discovery Therapeutics, Inc. | N-substituted 9-alkyladenines |
ES2334858T3 (es) * | 2000-08-10 | 2010-03-16 | Mitsubishi Tanabe Pharma Corporation | Derivados de prolina y uso de los mismos como farmacos. |
CA2462953C (en) | 2001-10-15 | 2011-01-04 | Janssen Pharmaceutica N.V. | Substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives and their use as selective non-peptide delta opioid agonists |
KR100967599B1 (ko) | 2001-10-15 | 2010-07-05 | 얀센 파마슈티카 엔.브이. | 허혈성 손상을 감소시키기 위한 치환된4-페닐-4-(1h-이미다졸-2-일)-피페리딘 유도체 |
DE60329513D1 (de) | 2002-07-30 | 2009-11-12 | Banyu Pharma Co Ltd | Antagonist des melanin-concentrating-hormone-rezeptors, enthaltend ein benzimidazolderivat als wirkstoff |
MXPA05003948A (es) * | 2002-10-17 | 2005-06-17 | Amgen Inc | Derivados de bencimidazol y su uso como ligandos de receptor vaniloide. |
US20070105890A1 (en) * | 2003-11-26 | 2007-05-10 | Dainippon Sumitomo Pharma Co., Ltd | Novel condensed imidazole derivative |
DE102004017932A1 (de) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
WO2006010283A1 (en) | 2004-07-28 | 2006-02-02 | Universität Zürich | Prevention and treatment of thrombus formation |
US20100267717A1 (en) | 2005-07-29 | 2010-10-21 | 4Sc Ag | Novel Heterocyclic NF-kB Inhibitors |
US7601745B2 (en) | 2004-09-27 | 2009-10-13 | 4Sc Ag | Heterocyclic NF-kB inhibitors |
DE102005012875B4 (de) | 2005-03-19 | 2006-11-16 | Sanofi-Aventis Deutschland Gmbh | Verwendung von Amino substituierten 8-N-Benzimidazolen |
DE102005012874A1 (de) * | 2005-03-19 | 2006-09-21 | Sanofi-Aventis Deutschland Gmbh | Amid substituierte 8-N-Benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
EP2368867B1 (en) * | 2005-04-06 | 2012-11-21 | North Carolina State University | Dense, shaped articles constructed of a refractory material |
EP1739078A1 (de) | 2005-05-30 | 2007-01-03 | Jerini AG | C5a-Rezeptor-Antagonisten |
JP2009510134A (ja) | 2005-10-07 | 2009-03-12 | ワラタ ファーマシューティカルズ, インコーポレイテッド | Dpp−iv阻害剤およびガストリン化合物の組み合わせ使用 |
US20090239880A1 (en) | 2006-07-03 | 2009-09-24 | Ulrik Svane Sorensen | Combinations of monoamine reuptake inhibitors and potassium channel activators |
WO2008023239A1 (en) | 2006-08-23 | 2008-02-28 | Pfizer Products Inc. | Pyrimidone compounds as gsk-3 inhibitors |
US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
WO2008100977A2 (en) | 2007-02-14 | 2008-08-21 | N.V. Organon | Carbamates therapeutic release agents as amidase inhibitors |
WO2008153701A1 (en) * | 2007-05-24 | 2008-12-18 | Schering Corporation | Compounds for inhibiting ksp kinesin activity |
JP2010535234A (ja) | 2007-07-30 | 2010-11-18 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 置換インドール |
WO2009089234A2 (en) | 2008-01-07 | 2009-07-16 | Auspex Pharmaceuticals | Substituted dibenzhydrylpiperazines |
KR20100101054A (ko) | 2009-03-07 | 2010-09-16 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
EP3682895A1 (en) | 2009-06-10 | 2020-07-22 | NoNO Inc. | Co-administration of an agent linked to a tat-internalization peptide with a mast cell degranulation inhibitor |
WO2011023812A1 (en) | 2009-08-27 | 2011-03-03 | Novasaid Ab | Microsomal prostaglandin e synthase-1 (mpges1) inhibitors |
EP2368876A1 (en) * | 2010-03-01 | 2011-09-28 | Sanofi | Derivatives of aminoindanes, their preparation and their application in therapeutics |
EP2651405A2 (en) | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
WO2012098281A2 (es) | 2011-01-19 | 2012-07-26 | Universidad Miguel Hernández De Elche | Péptidos moduladores de receptores trp y sus usos |
WO2012116440A1 (en) | 2011-03-03 | 2012-09-07 | Zalicus Pharmaceuticals Ltd. | Benzimidazole inhibitors of the sodium channel |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
EP2698367A1 (en) * | 2012-08-14 | 2014-02-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Benzimidazoles for the treatment of cancer |
GB201223265D0 (en) | 2012-12-21 | 2013-02-06 | Selvita Sa | Novel benzimidazole derivatives as kinase inhibitors |
WO2014127350A1 (en) | 2013-02-18 | 2014-08-21 | The Scripps Research Institute | Modulators of vasopressin receptors with therapeutic potential |
WO2014160183A1 (en) | 2013-03-13 | 2014-10-02 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
BR112015031073B1 (pt) | 2013-06-21 | 2022-11-29 | Zenith Epigenetics Ltd | Compostos inibidores bicíclicos de bromodomínio e composição farmacêutica contendo os referidos compostos |
US9828348B2 (en) | 2013-11-08 | 2017-11-28 | Purdue Pharma L.P. | Benzimidazole derivatives and use thereof |
ES2795748T3 (es) | 2014-07-31 | 2020-11-24 | Pasteur Institut Korea | Derivados de 2-amino-bencimidazol como inhibidores de 5-lipoxigenasa y/o prostaglandina E sintasa para tratar enfermedades inflamatorias |
US9630922B2 (en) | 2015-04-17 | 2017-04-25 | Forma Therapeutics, Inc. | 3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors |
WO2017052394A1 (en) | 2015-09-23 | 2017-03-30 | Uniwersytet Jagielloński | Imidazopyridine compounds and their use as 5-ht6 receptor ligands |
WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
WO2017064068A1 (en) | 2015-10-14 | 2017-04-20 | Almirall, S.A. | New trpa1 antagonists |
GB201603311D0 (en) | 2016-02-25 | 2016-04-13 | Jakobsson Per Johan | New uses and methods |
WO2018039384A1 (en) | 2016-08-23 | 2018-03-01 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators |
US10501421B1 (en) * | 2017-01-27 | 2019-12-10 | Vanderbilt University | Substituted benzimidazoles as modulators of Ras signaling |
-
2018
- 2018-10-18 KR KR1020207013744A patent/KR20200074965A/ko active IP Right Grant
- 2018-10-18 CN CN201880077655.5A patent/CN111417394B/zh active Active
- 2018-10-18 MX MX2020003993A patent/MX2020003993A/es unknown
- 2018-10-18 WO PCT/US2018/056484 patent/WO2019079578A1/en unknown
- 2018-10-18 BR BR112020007589A patent/BR112020007589A8/pt unknown
- 2018-10-18 AU AU2018351059A patent/AU2018351059B2/en active Active
- 2018-10-18 JP JP2020521577A patent/JP7450534B2/ja active Active
- 2018-10-18 US US16/754,349 patent/US11332459B2/en active Active
- 2018-10-18 CA CA3079081A patent/CA3079081A1/en active Pending
- 2018-10-18 IL IL273839A patent/IL273839B/en unknown
- 2018-10-18 SG SG11202003502VA patent/SG11202003502VA/en unknown
- 2018-10-18 EP EP18867844.5A patent/EP3697410A4/en active Pending
- 2018-10-18 MA MA050413A patent/MA50413A/fr unknown
- 2018-10-19 UY UY0001037941A patent/UY37941A/es not_active Application Discontinuation
- 2018-10-19 TW TW107137075A patent/TWI816704B/zh active
-
2020
- 2020-04-14 PH PH12020550265A patent/PH12020550265A1/en unknown
- 2020-04-16 CO CONC2020/0004669A patent/CO2020004669A2/es unknown
- 2020-04-16 CL CL2020001020A patent/CL2020001020A1/es unknown
- 2020-04-17 SA SA520411787A patent/SA520411787B1/ar unknown
Also Published As
Publication number | Publication date |
---|---|
WO2019079578A1 (en) | 2019-04-25 |
EP3697410A1 (en) | 2020-08-26 |
UY37941A (es) | 2019-04-30 |
CN111417394B (zh) | 2023-11-07 |
US11332459B2 (en) | 2022-05-17 |
BR112020007589A8 (pt) | 2022-08-02 |
CL2020001020A1 (es) | 2020-09-21 |
IL273839A (en) | 2020-05-31 |
MX2020003993A (es) | 2020-08-13 |
TW201930284A (zh) | 2019-08-01 |
AU2018351059A1 (en) | 2020-04-23 |
PH12020550265A1 (en) | 2021-03-01 |
IL273839B (en) | 2022-09-01 |
EP3697410A4 (en) | 2021-08-11 |
CN111417394A (zh) | 2020-07-14 |
BR112020007589A2 (pt) | 2020-09-24 |
TWI816704B (zh) | 2023-10-01 |
AU2018351059B2 (en) | 2022-05-12 |
KR20200074965A (ko) | 2020-06-25 |
US20200308145A1 (en) | 2020-10-01 |
CA3079081A1 (en) | 2019-04-25 |
SG11202003502VA (en) | 2020-05-28 |
SA520411787B1 (ar) | 2022-08-29 |
MA50413A (fr) | 2020-08-26 |
JP2021500332A (ja) | 2021-01-07 |
JP7450534B2 (ja) | 2024-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020004669A2 (es) | Derivados de bencimidazol y sus usos | |
DOP2022000124A (es) | Derivados de pirazolilo útiles como agentes anticancerígenos | |
ECSP22071009A (es) | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead | |
PE20151501A1 (es) | Inhibidores de prmt5 y sus usos | |
CO2021002977A2 (es) | Dimetilaminoazetidinaminas como inhibidores de jak | |
CL2020000610A1 (es) | Compuestos de bisamida que activan el sarcómero y sus usos. | |
UY38096A (es) | Inhibidores de arginasa y sus métodos de uso | |
UY35273A (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn | |
CO2021002976A2 (es) | Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak | |
MX2020011405A (es) | Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos. | |
BR112017016817A2 (pt) | derivados heterocíclicos formilados como inibidores de fgfr4 | |
UY37837A (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
CO2019002523A2 (es) | Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica | |
CU24434B1 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
BR112021011325A2 (pt) | Derivados de rapamicina | |
CU20190042A7 (es) | Compuestos derivados de naftiridinona | |
DOP2019000299A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
EA201891319A1 (ru) | Соединения алкилдигидрохинолинсульфонамида | |
CO2021001174A2 (es) | Inhibidores de ckd8/19 | |
DOP2020000088A (es) | Derivados de piridinona y su uso como inhibidores selectivos de alk2. | |
UY38133A (es) | Nuevos inhibidores de cdk8/19 | |
CL2022002490A1 (es) | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead | |
EA202090241A1 (ru) | Новые гетероциклические соединения как ингибиторы cdk8/19 | |
AR111416A2 (es) | Compuesto terapéutico para el dolor y síntesis del compuesto | |
CU20160170A7 (es) | Derivados de carboxamida |